Search Results

There are 1433 results for: content related to: The Selective Norepinephrine Reuptake Inhibitor Antidepressant Reboxetine: Pharmacological and Clinical Profile

  1. You have free access to this content
    Estimation of binding rate constants using a simultaneous mixed-effects method: application to monoamine transporter reuptake inhibitor reboxetine

    British Journal of Pharmacology

    Volume 160, Issue 2, May 2010, Pages: 389–398, Neil Benson, Nelleke Snelder, Bart Ploeger, Carolyn Napier, Harriet Sale, Nigel JM Birdsall, Richard P Butt and Piet H van der Graaf

    Version of Record online : 3 MAR 2010, DOI: 10.1111/j.1476-5381.2010.00719.x

  2. Lack of effect of reboxetine on cardiac repolarization

    Clinical Pharmacology & Therapeutics

    Volume 70, Issue 3, September 2001, Pages: 261–269, Joseph C. Fleishaker, Steven F. Francom, Beth D. Herman, Dean W. Knuth and Nkechi E. Azie

    Version of Record online : 27 SEP 2001, DOI: 10.1067/mcp.2001.117705

  3. Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans

    Clinical Pharmacology & Therapeutics

    Volume 66, Issue 4, October 1999, Pages: 374–379, Beth D. Herman, Joseph C. Fleishaker and Mark T. Brown

    Version of Record online : 14 OCT 1999, DOI: 10.1053/cp.1999.v66.a101207

  4. Hemodynamic effects of reboxetine in healthy male volunteers

    Clinical Pharmacology & Therapeutics

    Volume 66, Issue 3, September 1999, Pages: 282–287, Thierry Denolle, Cinzia Pellizzoni, M. Gabriella Jannuzzo and Italo Poggesi

    Version of Record online : 26 SEP 1999, DOI: 10.1016/S0009-9236(99)70036-6

  5. You have free access to this content
    The Promises and Pitfalls of Reboxetine

    CNS Drug Reviews

    Volume 9, Issue 4, December 2003, Pages: 327–342, Michelle E. Page

    Version of Record online : 7 JUN 2006, DOI: 10.1111/j.1527-3458.2003.tb00258.x

  6. The Norepinephrine Transporter Inhibitor Reboxetine Reduces Stimulant Effects of MDMA (“Ecstasy”) in Humans

    Clinical Pharmacology & Therapeutics

    Volume 90, Issue 2, August 2011, Pages: 246–255, CM Hysek, LD Simmler, M Ineichen, E Grouzmann, MC Hoener, R Brenneisen, J Huwyler and ME Liechti

    Version of Record online : 15 JUN 2011, DOI: 10.1038/clpt.2011.78

  7. Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics

    Biopharmaceutics & Drug Disposition

    Volume 20, Issue 1, January 1999, Pages: 53–57, Joseph C. Fleishaker, Massimiliano Mucci, Cinzia Pellizzoni and Italo Poggesi

    Version of Record online : 14 APR 1999, DOI: 10.1002/(SICI)1099-081X(199901)20:1<53::AID-BDD157>3.0.CO;2-P

  8. You have free access to this content
    Paroxetine versus other anti-depressive agents for depression

    Intervention Review

    The Cochrane Library

    Marianna Purgato, Davide Papola, Chiara Gastaldon, Carlotta Trespidi, Laura R Magni, Carla Rizzo, Toshi A Furukawa, Norio Watanabe, Andrea Cipriani and Corrado Barbui

    Published Online : 3 APR 2014, DOI: 10.1002/14651858.CD006531.pub2

  9. You have free access to this content
    The antidepressants citalopram and reboxetine reduce seizure frequency in rats with chronic epilepsy


    Volume 53, Issue 5, May 2012, Pages: 870–878, Katia Vermoesen, Ann Massie, Ilse Smolders and Ralph Clinckers

    Version of Record online : 16 MAR 2012, DOI: 10.1111/j.1528-1167.2012.03436.x

  10. Reboxetine, a selective noradrenaline reuptake inhibitor, is non-sedative and does not impair psychomotor performance in healthy subjects

    Human Psychopharmacology: Clinical and Experimental

    Volume 13, Issue 6, August 1998, Pages: 425–433, Werner M. Herrmann and Hermann Fuder

    Version of Record online : 21 DEC 1998, DOI: 10.1002/(SICI)1099-1077(199808)13:6<425::AID-HUP17>3.0.CO;2-R

  11. Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations

    Human Psychopharmacology: Clinical and Experimental

    Volume 13, Issue S1, February 1998, Pages: S29–S39, T. A. Ban, P. Gaszner, E. Aguglia, R. Batista, A. Castillo, A. Lipcsey, J.-P. Macher, A. Torres-Ruiz and L. Vergara

    Version of Record online : 21 DEC 1998, DOI: 10.1002/(SICI)1099-1077(199802)13:1+<S29::AID-HUP980>3.0.CO;2-D

  12. Separation of reboxetine enantiomers by means of capillary electrophoresis


    Volume 23, Issue 12, No. 12 June 2002, Pages: 1870–1877, Maria A. Raggi, Roberto Mandrioli, Cesare Sabbioni, Carlo Parenti, Giuseppe Cannazza and Salvatore Fanali

    Version of Record online : 2 JUL 2002, DOI: 10.1002/1522-2683(200206)23:12<1870::AID-ELPS1870>3.0.CO;2-R

  13. Reboxetine: tolerability and safety profile in patients with major depression

    Acta Psychiatrica Scandinavica

    Volume 101, Issue s402, June 2000, Pages: 37–40, Lars Tanum

    Version of Record online : 22 OCT 2003, DOI: 10.1034/j.1600-0447.2000.02606.x

  14. The need for new and better antidepressants: reboxetine a new option

    Acta Psychiatrica Scandinavica

    Volume 101, Issue s402, June 2000, Pages: 6–11, Sven J. Dencker

    Version of Record online : 22 OCT 2003, DOI: 10.1034/j.1600-0447.2000.02602.x

  15. You have free access to this content
    Chronic treatment with reboxetine by osmotic pumps facilitates its effect on extracellular noradrenaline and may desensitize α2-adrenoceptors in the prefrontal cortex

    British Journal of Pharmacology

    Volume 132, Issue 1, January 2001, Pages: 183–188, R W Invernizzi, S Parini, G Sacchetti, C Fracasso, S Caccia, K Annoni and R Samanin

    Version of Record online : 29 JAN 2009, DOI: 10.1038/sj.bjp.0703821

  16. Iodine-123 labeled reboxetine analogues for imaging of noradrenaline transporter in brain using single photon emission computed tomography


    Volume 66, Issue 11, November 2012, Pages: 923–930, Adriana Alexandre S. Tavares, Nicola K. Jobson, Deborah Dewar, Andrew Sutherland, Sally L. Pimlott, Jeffery Batis, Olivier Barret, John Seibyl and Gilles Tamagnan

    Version of Record online : 30 JUL 2012, DOI: 10.1002/syn.21585

  17. Pharmacokinetics of Single-Dose Reboxetine in Volunteers with Renal Insufficiency

    The Journal of Clinical Pharmacology

    Volume 40, Issue 5, May 2000, Pages: 482–487, Dr. François Coulomb, Dr. Francis Ducret, Mr. Jean-Paul Laneury, Dr. Francesco Fiorentini, Dr. Italo Poggesi, Dr. M. Gabriella Jannuzzo, Dr. Joseph C. Fleishaker, Dr. Georges Houin and Dr. Patrick Duchêne

    Version of Record online : 8 MAR 2013, DOI: 10.1177/00912700022009251

  18. Pharmacokinetics of reboxetine enantiomers in the dog


    Volume 9, Issue 3, 1997, Pages: 303–306, E. Frigerio, A. Benecchi, G. Brianceschi, C. Pellizzoni, I. Poggesi, M. Strolin Benedetti and P. Dostert

    Version of Record online : 7 DEC 1998, DOI: 10.1002/(SICI)1520-636X(1997)9:3<303::AID-CHIR17>3.0.CO;2-R

  19. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study

    Human Psychopharmacology: Clinical and Experimental

    Volume 21, Issue 5, July 2006, Pages: 337–345, Cengiz Akkaya, Enver Yusuf Sivrioglu, Semra Akgoz, Salih Saygin Eker and Selcuk Kirli

    Version of Record online : 20 JUL 2006, DOI: 10.1002/hup.770

  20. Behavior-dependent modulation of hippocampal EEG activity by the selective norepinephrine reuptake inhibitor reboxetine in rats


    Volume 17, Issue 8, August 2007, Pages: 627–633, Bernat Kocsis, Shaomin Li and Mihaly Hajos

    Version of Record online : 9 MAY 2007, DOI: 10.1002/hipo.20299